Business Wire

Mundipharma Welcomes the New Guidelines from ESC/EASD Recommending First-Line use of Sodium-Glucose Co-transporter-2 Inhibitors for Type 2 Diabetes Patients with Cardiovascular Disease

Share

As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), the Mundipharma network of independent associated companies welcomes the news that the sodium-glucose co-transporter-2 inhibitor (SGLT2i) class, which includes canagliflozin, has now been recommended in the newly published 2019 ESC (European Society of Cardiology) Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD (European Association for the Study of Diabetes) as a first-line treatment option for the management of patients with type 2 diabetes mellitus (T2DM), either drug naïve or on metformin, with atherosclerotic cardiovascular disease (ASCVD) or high/very high cardiovascular (CV) risk, which includes patients with other target organ damage (i.e. damage to the kidneys as predicted by important markers such as proteinuria and eGFR) and multiple other risk factors.1 Furthermore, SGLT2is are also recommended as a first-line treatment for patients with T2DM at high risk of heart failure (HF).1 The new guidelines were presented yesterday at the 2019 ESC Congress in Paris, France and have been published in the European Heart Journal.1

The updated guidelines took into account data from CV outcomes trials for SGLT2is which have demonstrated a range of CV benefits across the class. This includes the positive CV outcomes data for canagliflozin from the CANVAS Programme.2

The guidelines now recommend SGLT2is as a first-line treatment option for the prevention and management of chronic kidney disease (CKD) for patients with T2DM, who have a high associated risk of CV disease.1 Nephroprotection has been observed in recent CV outcome trials, including the CREDENCE study, which found canagliflozin plus standard of care reduced the relative risk of the primary renal and cardiovascular outcomes compared with placebo plus standard of care.3 Canagliflozin is currently under review by the European Medicines Agency (EMA) to extend its licence for use in the T2DM with CKD patient population.

“It is exciting to see that the recent positive results from CV outcomes trials of SGLT2is in patients with type 2 diabetes have been reflected in the updated ESC/EASD guidelines,” commented Professor Antonio Ceriello, Head of Diabetes Research Department, IRCCS MultiMedica, Milan, Italy. “It is important for clinicians to now recognise that initiating an SGLT2i, such as canagliflozin, as a first line therapy in patients with certain types of CV disease, or target organ damage, may improve long-term patient outcomes.”

Approximately 58 million people in Europe currently live with T2DM, which is set to rise to 67 million by 2045.5 If left untreated, patients are at greater risk of developing serious health complications, such as renal disease, HF, and CV disease which is the most common cause of death for T2DM patients.4

“Cardiovascular disease is a major complication of type 2 diabetes which puts patients’ lives at risk and is a significant burden on healthcare systems across Europe. With the new guidelines, clinicians can make the best treatment decisions and transform the standard of care for their patients.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma.

The updated guidelines can be viewed at: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Diabetes-Pre-Diabetes-and-Cardiovascular-Diseases-developed-with-the-EASD.

-END-

Notes to the editors:

About the Guidelines1
The European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) convened a panel to update the existing guidelines, published in 2013, on the management of diabetes, pre-diabetes and cardiovascular diseases. The updated guidelines were published in the European Heart Journal and were presented during the annual meeting of ESC in Paris, France, on the 2nd September 2019.

About Invokana®6
Invokana® (canagliflozin) is an oral, once-daily medication which belongs to a class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors work by inhibiting SGLT2, which promotes the loss of glucose via the urine, lowering blood glucose levels in adults with T2DM. Invokana was approved in the European Union by the European Commission in November 2013. It is indicated for the treatment of adults with insufficiently controlled T2DM as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications and in addition to other medicinal products for the treatment of diabetes. Approval was based on a comprehensive global Phase III clinical trial programme.

About Vokanamet®7
Vokanamet® (a fixed-dose combination of canagliflozin and metformin) is approved in the European Union for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. Vokanamet combines two oral glucose-lowering medicinal products with different and complementary mechanisms of action.

About the CANVAS Programme2
The CANVAS Programme (N=10,142) comprised the two large canagliflozin cardiovascular outcome trials, CANVAS and CANVAS-R, and included a pre-specified integrated analysis of these two studies to evaluate the potential for CV protection of canagliflozin in patients with T2DM who had either a prior history of CV disease or at least two CV risk factors. The integrated analysis also evaluated the effects of canagliflozin on renal and safety outcomes.

Canagliflozin met the primary outcome by significantly reducing the rates of the composite of major adverse CV events (MACE) comprised of CV mortality, non-fatal myocardial infarction (MI), or non-fatal stroke (26.9 vs. 31.5/1000 patient-years, hazard ratio (HR) 0.86; 95% confidence interval (CI 0.75-0.97; P<0.0001 for non-inferiority; P=0.0158 for superiority) compared with placebo plus standard of care, respectively. All 3 components of MACE composite (CV death, non-fatal MI, and non-fatal stroke) exhibited point estimates of effect suggesting benefit with canagliflozin.

Adverse events reported in the CANVAS Programme were generally consistent with the known safety profile of canagliflozin. Whilst an increase in lower limb amputation and bone fractures were observed in the CANVAS Programme, this signal was not observed in further long term clinical trial data involving high risk patients.3

About the CREDENCE Clinical Trial3
The CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study was the first dedicated and fully recruited renal outcome trial evaluating renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) with a sodium glucose co-transporter 2 (SGLT2) inhibitor. It was a phase 3 randomised, double-blind, event-driven, placebo-controlled, parallel-group, 2 arm multi-centre study of the effects of canagliflozin on renal and cardiovascular outcomes in subjects with T2DM and CKD. In particular, it compared the efficacy and safety of canagliflozin versus placebo at preventing clinically important kidney and cardiovascular outcomes in patients with T2DM and CKD when used in addition to standard of care, including a maximum tolerated daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

About the Mundipharma network
Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. With a high performing and learning organisation that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars.

Invokana® and Vokanamet® are registered trademarks of Janssen

References:


1 European Society of Cardiology (ESC). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2019);00,1-69.

2 Neal B et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine (2017);377:644-657.

3 Perkovic, V. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephrology. The New England Journal of Medicine. 2019; 380(24): 2295-2306.

4 Fan, W. Epidemiology in diabetes mellitus and cardiovascular disease. Cardiovascular Endocrinology & Metabolism. 2017;6(1):8-16.

5 IDF Diabetes Atlas Eighth Edition 2017. Available at: http://diabetesatlas.org/resources/2017-atlas.html. Last accessed September 2019.

6 Invokana SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/invokana-epar-product-information_en.pdf Last accessed September 2019

7 Vokanamet SmPC. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors 20/European_Commission_final_decision/WC500206514.pdf. Last accessed September 2019

Job code: MBL/DIAB-19025
Date of preparation: September 2019

Contact information

Cendrine Banerjee-Quetel
Asset Communications Associate, Mundipharma International Ltd
Email: Cendrine.Banerjee-Quetel.external@mundipharma.com
Tel: +44 (0) 1223 393 009

Abbie Bell
Senior Account Manager, Havas SO
E-mail: HavasSO-Mundipharma@havasso.com
Tel: +44 (0) 20 3196 9919
Mob: +44 7375 660 515

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Generation in Cryptocurrency Mining by BitHarp23.9.2019 17:45:00 EESTPress release

Lyre Miner and Harp Miner, two recently released cryptocurrency mining rigs from www.BitHarp.com ( BitHarp Group Limited ), are quickly turning out to be gamechangers in the global crypto market. Within their short lifespan, these two products have shown promises of revolutionizing this thriving industry by offering superfast ROI for seasoned miners as well as beginners looking to try their hand at crypto mining. The ability of Lyre Miner and Harp Miner to generate quick return on investment can be attributed to the high hash rates of the products. The term hash rate may be referred to as the speed at which a given mining machine operates. A higher hash rate increases the opportunity of a miner to find the next block and receive the reward. Making things even better for the miners, Lyre Miner and Harp Miner have significantly low energy consumptions of 600W and 2400 W respectively. The hash rate powers offered by Lyre Miner and Harp Miner are mentioned below at a glance. Lyre Miner: 33

Jabil Photonics to Demonstrate Coherent SiP based 100G/200G CFP2-DCO Product at ECOC 201923.9.2019 15:48:00 EESTPress release

Jabil (NYSE: JBL) today announced that its Photonics business unit, a leading provider of customized end-to-end design, manufacturing and test solutions for optical communication products, will be demonstrating its coherent 100G/200G CFP2-DCO module this week at the ECOC Exhibition (Hall 4, Booth 498) in Dublin, Ireland. Jabil’s CFP2-DCO is a hot-pluggable module designed to support single-wavelength data coherent transmission at 100Gbps using DP-QPSK and 200Gbps using DP-16QAM modulations. The CFP2-DCO is designed for DWDM networks ranging from metro and data-center interconnect (DCI) to long-haul applications, as well as 100Gbps point-to-point (P2P) coherent solutions for unamplified links in 5G and cable access networks up to 80km. Powered by Elenion Technologies’ next generation Silicon Photonics (SiP) coherent engine, the Jabil Photonics CFP2-DCO sets a new standard for price-performance. The module incorporates an ultra-narrow linewidth external cavity micro-ITLA laser with gridl

CE China 2019: Suning Launches New Biu Products23.9.2019 15:43:00 EESTPress release

Premiere at CE China: The Chinese retail giant Suning, strategic partner of CE China, has seized the opportunity to present eight new products of its Biu product line for smart home appliances at the CE China in Guangzhou. On this occasion, fans of Biu were invited to the first ever Biu fan festival to attend the launch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190923005490/en/ Suning Launches New Biu Products at CE China 2019 (Graphic: Business Wire) Behind closed curtains, selected Biu-fans were the first to learn about the premieres of intelligent smart home products at the booth of Suning on the trade show. Among others, Suning presented the new Biu air conditioner as a “pro version”, the "Little Dolphin" electric water heater and the "Little Seashells" gas water heater. Suning representatives also showed, how the different devices connect with each other. According to Suning, Biu will continue to focus on smart pr

FLIR Introduces M300 Series Marine Cameras23.9.2019 15:00:00 EESTPress release

FLIR Systems (NASDAQ: FLIR) today announced the FLIR M300 Series, a new generation of maritime thermal cameras delivering advanced awareness-enhancing technologies, safer navigation, and seamless integration with onboard boat systems. FLIR M300 Series cameras are designed for the most demanding professional mariners and first responders who operate in the harshest marine environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190923005214/en/ FLIR M300 Series thermal imaging cameras for professional mariners and first responders provide safer navigation and increased situational awareness (Photo: Business Wire) The successor to FLIR’s industry-leading M-Series of maritime cameras, the next generation M300 Series consists of five models featuring rugged and robust new pan and tilt housings – four models with the FLIR Boson™ resolution thermal camera cores, plus a visible-only, high-definition (HD) model. The series is hi

Mary Kay, in Collaboration With UN Agencies, Launches Women’s Entrepreneurship Accelerator23.9.2019 15:00:00 EESTPress release

Today, Mary Kay Inc., a leading advocate of women’s empowerment and entrepreneurship, announced the Women’s Entrepreneurship Accelerator, a multi-partner initiative designed to inspire, educate, and empower women entrepreneurs around the world. With no qualifying barriers to participate, the ground-breaking initiative is a strategic collaboration developed in consultation with six United Nations agencies: UN Women, United Nations Office for Partnerships (UNOP), International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), and the United Nations Development Programme (UNDP). The Accelerator will offer a guided digital curriculum supplemented by on-the-ground training and mentorship. In addition, it will serve as an advocacy platform to eliminate entrepreneurial roadblocks for women, ranging from digital literacy to legal reform—enabling women to fully participate in the growth of their local and national economies. The Accelerator will support glob

Western Union Expands Global Real-time Payment Capabilities for Millions of Consumers and Business Accounts23.9.2019 15:00:00 EESTPress release

Sibos Conference – Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement, today announced availability of its real-time cross-border platform to accelerate international consumer, consumer-to-business and business-to-consumer payments to eligible accounts, cards and digital wallets. The announcement marks an expansion of Western Union’s unique ability to leverage its core assets – including global settlement capabilities, network, compliance and technology systems – to enable international cross-border payments in minutes across multiple currencies. Globally recognized for daily cross-currency management and settlement via its vast retail network across 20,000 corridors or pairs of countries for consumers in local currency, the company’s expanded money in minutes platform will now power next-generation cross-border payment experiences for consumers and businesses across a multitude of sectors. “This is a prime example of how the global reach, inter-connected

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom